Nov2024
Ariana reaffirms its position on drug development and publishes its new manifesto.
We all share the same challenge: finding the right therapy for the right patient. Yet, failures remain frequent, costs continue to soar and over 12,000 diseases still have no treatment. What if you reimagine your drug development process with eXplainable AI? A methodology where the amount of available data doesn’t matter because we go beyond […]
Nov2024
Ariana Pharma enters a new era with Dr. Pascale Bouillé taking the helm of the company.
Pascale Bouillé is the CEO of Ariana Pharma, where she leverages her extensive expertise in biotechnology to drive innovation and deliver impactful solutions in data-driven drug development. Her career spans significant achievements in both academia and entrepreneurship, reflecting a unique ability to transform cutting-edge scientific discoveries into successful commercial ventures. Before joining Ariana Pharma, Pascale […]
Oct2024
CorpusAnalytiX and Ariana Pharma Announce Collaborative Alliance to Accelerate AI-Driven Drug Development
Collaboration connects CorpusAnalytiX’s diverse healthcare data marketplace with Ariana Pharma’s Knowledge Extraction and Management eXplainable AI platform to fuel advanced pharmaceutical research. October 15, 2024 – LONDON and PARIS: CorpusAnalytiX, a transformative healthcare data brokerage platform, and Ariana Pharma, a leading AI drug development company, today announced a strategic partnership to accelerate drug development and […]
Sep2024
Passing of Dr. Mohammad Afshar, Founder of Ariana Pharma
It is with profound sadness that we announce the passing of our founder, CEO and Chairman, Dr. Mohammad Afshar, on August 8th, 2024.
Dr. Afshar was a visionary leader, as well as a physician, researcher, entrepreneur, and pioneer in the field of AI and healthcare.
May2024
Ariana is 20… we’ve come a long way
Cast your mind back to when Ariana was founded… Facebook was just launching, Data Scientist had yet to be declared “the sexiest job of the 21st century,” and AI was nowhere near as widespread as today. I vividly recall a potential client asking me, “Why do you do this? This is data torture!” We talked […]
Apr2024
Ariana Pharma announces important Artificial Intelligence (AI) collaboration in precision oncology to accelerate a first-in class antibody blocking lipid metabolism for the treatment of advanced cancer
Artificial Intelligence and organoid data to accelerate the development of a first-in-class antibody in precision oncology. Paris, France and Cambridge, MA, USA, 16th April, 2024, Ariana Pharma, a leading Artificial Intelligence drug development company, announced today that it has entered a €3 million consortium sponsored by the Eurostars 3 program, led by ONA Therapeutics SL, […]
Mar2024
Ariana Pharma Announces Major Artificial Intelligence Collaboration in Cell Therapy with Leading Academic Partners Targeting Immune Regulatory T Cells
Explainable Artificial Intelligence and multi-modal clinical and omic investigations in immunotherapy applied to organ transplantation. Paris, France and Cambridge, MA, USA, March 1st, 2024. Ariana® Pharma a leading Artificial Intelligence drug development company announced today that it has entered a $10 million funded Artificial Intelligence-driven Cell Therapy collaboration with Assistance Publique – Hôpitaux de Paris (AP-HP), […]
Nov2023
ESMO 2023: Advances in the fight against cancer through artificial intelligence.
The collaboration between Ariana Pharma, Omicure, and the Léon Bérard Center has led to a breakthrough in identifying survival biomarkers across various cancer types using eXplainable Artificial Intelligence. In a study, presented at ESMO 2023 [Identification of biomarkers of survival across multiple cancer types using eXplainable Artificial Intelligence], KEM®, a proprietary Ariana Pharma technology, was […]
May2023
Ariana Pharma continues to bolster Scientific Advisory Board by adding world-leading Oncologist Pr. Jean-Yves BLAY
Ariana Pharma is a leading Artificial Intelligence (AI) drug development company. Using its KEM® Artificial Intelligence (eXp.AI) technology, Ariana helps its partners introduce personalized medicine clinical trial design into their protocols and optimize clinical endpoints, identify biomarkers of therapeutic response and potential synergistic therapies. Ariana routinely collects and combines clinical data with omic data, immunological […]
Mar2023
Ariana Pharma strengthens SAB with appointment of world-leading Neurologist Jacques Touchon
Cambridge, MA, USA and Paris, France, March 27, 2023 – Ariana Pharma, the leading Al-driven precision medicine company, has announced the appointment of Professor Jacques Touchon to its Scientific Advisory Board.